Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice

Molecular and Cellular Biology

Volumn 25, Issue 8, 2005, Pages 3163-3172

  Rankin, Erinn B ^a   Higgins, Debra F ^a   Walisser, Jacqueline A ^b   Johnson, Randall S ^c   Bradfield, Christopher A ^b   Haase, Volker H ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d 700 Clinical Research Bldg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR PROTEIN; CARRIER PROTEIN; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2; PHOSPHOGLYCERATE KINASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; HEMANGIOMA; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; POLYCYTHEMIA; PRIORITY JOURNAL; VASCULAR TUMOR; VON HIPPEL LINDAU DISEASE;

ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; DNA-BINDING PROTEINS; ERYTHROPOIETIN; GENE DELETION; GENE EXPRESSION; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HEMANGIOMA, CAVERNOUS; HEPATOCYTES; HIPPEL-LINDAU DISEASE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER; LIVER NEOPLASMS; MICE; MICE, KNOCKOUT; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYCYTHEMIA; RECEPTORS, ARYL HYDROCARBON; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 16244381736     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.8.3163-3172.2005     Document Type: Article

References (65)

1. Camenisch, G., R. H. Wenger, and M. Gassmann. 2002. DNA-binding activity of hypoxia-inducible factors (HIFs). Methods Mol. Biol. 196:117-129.
2. Chilov, D., G. Camenisch, I. Kvietikova, U. Ziegler, M. Gassmann, and R. H. Wenger. 1999. Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1α. J. Cell Sci. 112:1203-1212.
3. Clifford, S. C., M. E. Cockman, A. C. Smallwood, D. R. Mole, E. R. Woodward, P. H. Maxwell, P. J. Ratcliffe, and E. R. Maher. 2001. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10:1029-1038.
4. Cohen, D. E., and J. T. Lee. 2002. X-chromosome inactivation and the search for chromosome-wide silencers. Curr. Opin. Genet. Dev. 12:219-224.
5. Da Silva, J. L., C. Lacombe, P. Bruneval, N. Casadevall, M. Leporrier, J. P. Camilleri, J. Bariety, P. Tambourin, and B. Varet. 1990. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 75:577-582.
6. Duan, D. R., A. Pause, W. H. Burgess, T. Aso, D. Y. Chen, K. P. Garrett, R. C. Conaway, J. W. Conaway, W. M. Linehan, and R. D. Klausner. 1995. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402-1406.
7. Flamme, I., M. Krieg, and K. H. Plate. 1998. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2α. Am. J. Pathol. 153:25-29.
8. Gnarra, J. R., K. Tory, Y. Weng, L. Schmidt, M. H. Wei, H. Li, F. Latif, S. Liu, F. Chen, F. M. Duh, et al. 1994. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7:85-90.
9. Gnarra, J. R., J. M. Ward, F. D. Porter, J. R. Wagner, D. E. Devor, A. Grinberg, M. R. Emmert-Buck, H. Westphal, R. D. Klausner, and W. M. Linehan. 1997. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. USA 94:9102-9107.
10. Haase, V. H., J. N. Glickman, M. Socolovsky, and R. Jaenisch. 2001. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. USA 98:1583-1588.
11. Hayasaka, K., Y. Tanaka, T. Satoh, and H. Mutoh. 1999. Hepatic hemangioblastoma: an unusual presentation of von Hippel-Lindau disease. J. Comput. Assist. Tomogr. 23:565-566.
12. Hergovich, A., J. Liszrwan, R. Barry, P. Ballschmieter, and W. Krek. 2003. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat. Cell Biol. 5:64-70.
13. Herman, J. G., F. Latif, Y. Weng, M. I. Lerman, B. Zbar, S. Liu, D. Samid, D. S. Duan, J. R. Gnarra, W. M. Linehan, et al. 1994. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 91:9700-9704.
14. Hes, F. J., R. B. van der Luijt, and C. J. Lips. 2001. Clinical management of Von Hippel-Lindau (VHL) disease. Neth. J. Med. 59:225-234.
15. Hoffman, M. A., M. Ohh, H. Yang, J. M. Klco, M. Ivan, and W. G. Kaelin, Jr. 2001. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10:1019-1027.
16. Hu, C. J., L. Y. Wang, L. A. Chodosh, B. Keith, and M. C. Simon. 2003. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol. Cell. Biol. 23:9361-9374.
17. Iliopoulos, O., A. P. Levy, C. Jiang, W. G. Kaelin, Jr., and M. A. Goldberg. 1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA 93:10595-10599.
18. 2 sensing. Science 292:464-468.
19. Iwai, K., K. Yamanaka, T. Kamura, N. Minato, R. C. Conaway, J. W. Conaway, R. D. Klausner, and A. Pause. 1999. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. USA 96:12436-12441.
20. 2-regulated prolyl hydroxylation. Science 292:468-472.
21. Jain, S., E. Maltepe, M. M. Lu, C. Simon, and C. A. Bradfield. 1998. Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. Mech. Dev. 73:117-123.
22. Kaelin, W. G., Jr. 2002. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2:673-682.
23. Kamura, T., D. M. Koepp, M. N. Conrad, D. Skowyra, R. J. Moreland, O. Iliopoulos, W. S. Lane, W. G. Kaelin, Jr., S. J. Elledge, R. C. Conaway, J. W. Harper, and J. W. Conaway. 1999. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284:657-661.
24. Kewley, R. J., M. L. Whitelaw, and A. Chapman-Smith. 2004. The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. Int. J. Biochem. Cell Biol. 36:189-204.
25. Kibel, A., O. Iliopoulos, J. A. DeCaprio, and W. G. Kaelin, Jr. 1995. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269:1444-1446.
26. Kietzmann, T., Y. Cornesse, K. Brechtel, S. Modaressi, and K. Jungermann. 2001. Perivenous expression of the mRNA of the three hypoxia-inducible factor alpha-subunits, HIF1α, HIF2α and HIF3α, in rat liver. Biochem. J. 354:531-537.
27. Kondo, K., W. Y. Kim, M. Lechpammer, and W. G. Kaelin, Jr. 2003. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1:E83.
28. Kondo, K., J. M. Klco, E. Nakamura, M. Lechpammer, and W. G. Kaelin. 2002. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1:237-246.
29. Krieg, M., R. Haas, H. Brauch, T. Acker, I. Flamme, and K. H. Plate. 2000. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19:5435-5443.
30. Krieg, M., H. H. Marti, and K. H. Plate. 1998. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 92:3388-3393.
31. Laird, P. W., A. Zijderveld, K. Linders, M. A. Rudnicki, R. Jaenisch, and A. Berns. 1991. Simplified mammalian DNA isolation procedure. Nucleic Acids Res. 19:4293.
32. Ma, W., L. Tessarollo, S. B. Hong, M. Baba, E. Southon, T. C. Back, S. Spence, C. G. Lobe, N. Sharma, G. W. Maher, S. Pack, A. O. Vortmeyer, C. Guo, B. Zbar, and L. S. Schmidt. 2003. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res. 63:5320-5328.
33. MacGregor, G. R., B. P. Zambrowicz, and P. Soriano. 1995. Tissue non-specific alkaline phosphatase is expressed in both embryonic and extraembryonic lineages during mouse embryogenesis but is not required for migration of primordial germ cells. Development 121:1487-1496.
34. Maher, E. R., and W. G. Kaelin, Jr. 1997. von Hippel-Lindau disease. Medicine (Baltimore) 76:381-391.
35. Maranchi, J. K., J. R. Vasselli, J. Riss, J. S. Bonifacio, W. M. Linehan, and R. D. Klausner. 2002. The contribution of VHL substrate binding and HIF-1α to the phenotype of vhl loss in renal cell carcinoma. Cancer Cell 1:247-253.
36. Martinez, A., P. Fullwood, K. Kondo, T. Kishida, M. Yao, E. R. Maher, and F. Latif. 2000. Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. Mol. Pathol. 53:137-144.
37. Maxwell, P. H., G. U. Dachs, J. M. Gleadle, L. G. Nicholls, A. L. Harris, I. J. Stratford, O. Hankinson, C. W. Pugh, and P. J. Ratcliffe. 1997. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94:8104-8109.
38. Maxwell, P. H., M. S. Wiesener, G. W. Chang, S. C. Clifford, E. C. Vaux, M. E. Cockman, C. C. Wykoff, C. W. Pugh, E. R. Maher, and P. J. Ratcliffe. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275.
39. Maynard, M. A., H. Qi, J. Chung, E. H. Lee, Y. Kondo, S. Hara, R. C. Conaway, J. W. Conaway, and M. Ohh. 2003. Multiple splice variants of the human HIF-3α locus are targets of the VHL E3 ubiquitin ligase complex. J. Biol. Chem. 21:21.
40. McGrath, F. P., R. G. Gibney, D. C. Morris, D. A. Owen, and S. R. Erb. 1992. Case report: multiple hepatic and pulmonary haemangioblastomas - a new manifestation of von Hippel-Lindau disease. Clin. Radiol. 45:37-39.
41. Ohh, M., R. L. Yauch, K. M. Lonergan, J. M. Whaley, A. O. Stemmer-Rachamimov, D. N. Louis, B. J. Gavin, N. Kley, W. G. Kaelin, Jr., and O. Iliopoulos. 1998. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1:959-968.
42. Patel, Y. M., J. S. Yun, J. Liu, M. M. McGrane, and R. W. Hanson. 1994. An analysis of regulatory elements in the phosphoenolpyruvate carboxykinase (GTP) gene which are responsible for its tissue-specific expression and metabolic control in transgenic mice. J. Biol. Chem. 269:5619-5628.
43. Pause, A., S. Lee, R. A. Worrell, D. Y. Chen, W. H. Burgess, W. M. Linehan, and R. D. Klausner. 1997. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA 94:2156-2161.
44. Pavlovich, C. P., and L. S. Schmidt. 2004. Searching for the hereditary causes of renal-cell carcinoma. Nat. Rev. Cancer 4:381-393.
45. Postic, C., M. Shiota, K. D. Niswender, T. L. Jetton, Y. Chen, J. M. Moates, K. D. Shelton, J. Lindner, A. D. Cherrington, and M. A. Magnuson. 1999. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem. 274:305-315.
46. Rojiani, A. M., D. A. Owen, K. Berry, B. Woodhurst, F. H. Anderson, C. H. Scudamore, and S. Erb. 1991. Hepatic hemangioblastoma. An unusual presentation in a patient with von Hippel-Lindau disease. Am. J. Surg. Pathol. 15:81-86.
47. Ruschitzka, F. T., R. H. Wenger, T. Stallmach, T. Quaschning, C. de Wit, K. Wagner, R. Labugger, M. Kelm, G. Noll, T. Rulicke, S. Shaw, R. L. Lindberg, B. Rodenwaldt, H. Lutz, C. Bauer, T. F. Luscher, and M. Gassmann. 2000. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc. Natl. Acad. Sci. USA 97:11609-11613.
48. Ryan, H. E., M. Poloni, W. McNulty, D. Elson, M. Gassmann, J. M. Arbeit, and R. S. Johnson. 2000. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 60:4010-4015.
49. -/- mice. Nat. Genet. 35:331-340.
50. Semenza, G. L. 2001. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 13:167-171.
51. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15:551-578.
52. Soriano, P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21:70-71.
53. Sowter, H. M., R. R. Raval, J. W. Moore, P. J. Ratcliffe, and A. L. Harris. 2003. Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia. Cancer Res. 63:6130-6134.
54. Staller, P., J. Sulitkova, J. Lisztwan, H. Moch, E. J. Oakeley, and W. Krek. 2003. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425:307-311.
55. Stroka, D. M., T. Burkhardt, I. Desbaillets, R. H. Wenger, D. A. Neil, C. Bauer, M. Gassmann, and D. Candinas. 2001. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 15:2445-2453.
56. Vogel, J., I. Kiessling, K. Heinicke, T. Stallmach, P. Ossent, O. Vogel, M. Aulmann, T. Frietsch, H. Schmid-Schonbein, W. Kuschinsky, and M. Gassmann. 2003. Transgenic mice overexpressing erythropoietin adapt to excessive erythrocytosis by regulating blood viscosity. Blood 102:2278-2284.
57. Vortmeyer, A. O., S. Frank, S. Y. Jeong, K. Yuan, B. Ikejiri, Y. S. Lee, D. Bhowmick, R. R. Lonser, R. Smith, G. Rodgers, E. H. Oldfield, and Z. Zhuang. 2003. Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res. 63:7051-7055.
58. Vortmeyer, A. O., J. R. Gnarra, M. R. Emmert-Buck, D. Katz, W. M. Linehan, E. H. Oldfield, and Z. Zhuang. 1997. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangio-blastoma associated with von Hippel-Lindau disease. Hum. Pathol. 28:540-543.
59. Wagner, K. F., D. M. Katschinski, J. Hasegawa, D. Schumacher, B. Meller, U. Gembruch, U. Schramm, W. Jelkmann, M. Gassmann, and J. Fandrey. 2001. Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 97:536-542.
60. Walisser, J. A., M. K. Bunger, E. Glover, E. B. Harstad, and C. A. Bradfield. 2004. Patent ductus venosus and dioxin resistance in mice harboring a hypomorphic Arnt allele. J. Biol. Chem. 279:16326-16331.
61. Warnecke, C., Z. Zaborowska, J. Kurreck, V. A. Erdmann, U. Frei, M. Wiesener, and K. U. Eckardt. 2004. Differentiating the functional role of hypoxia-inducible factor (HIF)-1α and HIF-2α (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2α target gene in Hep3B and Kelly cells. FASEB J. 18:1462-1464.
62. 2-regulated gene expression. FASEB J. 16:1151-1162.
63. Wiesener, M. S., J. S. Jurgensen, C. Rosenberger, C. K. Scholze, J. H. Horstrup, C. Warnecke, S. Mandriota, I. Bechmann, U. A. Frei, C. W. Pugh, P. J. Ratcliffe, S. Bachmann, P. H. Maxwell, and K. U. Eckardt. 2003. Widespread hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs. FASEB J. 17:271-273.
64. Wiesener, M. S., P. M. Munchenhagen, I. Berger, N. V. Morgan, J. Roigas, A. Schwiertz, J. S. Jurgensen, G. Gruber, P. H. Maxwell, S. A. Loning, U. Frei, E. R. Maher, H. J. Grone, and K. U. Eckardt. 2001. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1α in clear cell renal carcinomas. Cancer Res. 61:5215-5222.
65. -/- tumors. Mol. Cancer Res. 2:89-95.